The use of cyclosporine-A/methotrexate (CyA/MTX) for graft-versus-host disease (GVHD) prophylaxis is safe and effective for patients undergoing allogeneic bone marrow transplantation after preparation with cyclophosphamide and total body irradiation. We report 87 patients prepared for allogeneic transplant with busulfan 4 mg/kg/d orally for 4 days, followed by cyclophosphamide 60 mg/ kg/d intravenously for 2 days (BuqCy2). A marked increase in hepatotoxicity was observed in 20 patients administered CyA/MTX, compared with 67 historical control patients who received CyA/ methylprednisolone (CyAl MP) for GVHD prophylaxis with all other treatment and support variables remaining constant. The incidence of hyperbilirubinemia (bilirubin 2 2
In recent years a number of alternative regimens for transplantation, and GVHD prophylaxis, have been investigated. One such regimen uses busulfan, 4 mg/kg/d orally for 4 days, followed by CTX, 60 mg/kg/d administered intravenously (IV) for 2 days (BuqCyz), using CyA and methylprednisolone (MP) for GVHD prophylaxis.8 VOD has been reported to occur in 2% to 11% of patients so treated.8, 9 We now report our experience using Bu4Cy2 showing a marked increase in the incidence, and severity of, VOD for patients who received CyAIMTX for GVHD prophylaxis versus CyAIMP.
MATERIALS AND METHODS
All patients were entered on a study protocol that had been reviewed and approved by the Wilford Hall US Air Force (USAF) Medical Center Institutional Review Board.
Between October 31, 1986 and June 26, 1990,90 consecutive patients underwent allogeneic BMT preparation with Bu4Cyz at Wilford Hall USAF Medical Center. Patients received busulfan orally at a dose of 1 mglkg of ideal body weight every 6 hours daily for 4 consecutive days (-7 through -4) for a total dose of 16 mglkg. Thereafter, CTX was administered intravenously over 1 hour at a dose of 60 mg/kg ideal body weight for 2 consecutive days (-3 and -2)s Donor bone marrow was infused 2 days after the last dose of CrrX (day 0). Three patients were not included for further analysis because of the presence of active liver disease, as defined by a bilirubin greater than 2 mg/dL, at the time of transplantation.
Before beginning the preparative regimen, all patients were sterilely bathed and placed into strict isolation in laminar air flow (LAF) rooms. Patients remained in LAF until all criteria were met for discharge for outpatient follow-up, or development of medical problems requiring intensive care. Nonabsorbable antibiotics for 'gut decontamination' were not used. A 'low bacterial' diet was used while in LAF. All patients received commercial Ig preparations at a dose of 500 mg/kg IV beginning on day -8 every 2 weeks until day 100, and orally beginning on day 0 at a dose of 50 mgikg daily in four divided doses until discharge from LAF. Colony-stimulating factors were not used. All patients received oral clotrimazole and trimethoprim-sulfamethoxazole (TIS). Patients receiving MP for GVHD prophylaxis took one double-strength TIS tablet twice a day beginning on day -7 and continued until their absolute neutrophil count ( A N C ) was greater than l,000/mm3, after which the schedule was changed to 3 days per week for 1 year, as tolerated. Patients receiving MTX for GVHD prophylaxis received the same dose from days -9 to -2, at which point the drug was stopped until their ANC was greater than l,000/mm3, with the subsequent schedule the same as above. All blood products transfused were obtained from volunteer donors who had a negative antibody titer against cytomegalovirus. A single intrathecal dose of 12 mg MTX was administered to patients undergoing transplantation for acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML)-lymphoid blast crisis, and acute myelogenous leukemia-French-American-British (AML-FAB) M4/Ms or initial white blood count (WBC) greater than Acute GVHD was assessed according to the grading system described in the literature.lo All patients surviving at least 30 days, or who developed acute GVHD regardless of time of onset, were included in the analysis for GVHD.
Sixty-seven patients who underwent transplant operations between October 31,1986 and November 22,1989 received CyA/MP to prevent GVHD. CyA started at midnight of the day of transplantation and was administered as a continuous infusion at the dose of 5 mg/kg/d for 96 hours. Thereafter, the dose was reduced to 3 mg/kg/d administered IV over 6 hours until day 14. Between days 14 and 35, the CyA dose was increased to 3.75 mgikg administered IV, or orally at four times the IV dose upon discharge. During the initial 35 days, doses were adjusted to maintain the whole blood CyA level between 400 and 1,000 ng/mL. Thereafter, CyA was slowly tapered until day 180, when it was discontinued. MP was started on day 7 at a dose of 0.5 mg/kg/d administered IV. On day 14, the MP dose was increased to 1 mgikgld through day 28 and administered orally in an equivalent dose of prednisone on discharge from LAF. Between days 28 and 72, the corticosteroid was slowly tapered and discontinued. 8 Twenty patients received CyAiMTX as an alternate standard acute GVHD prophylactic regimen. Four patients with CML who had transplants between June 8,1989 and November 22,1989 were the first to receive CyA/MTX because of an unexplained increased incidence of acute GVHD that we have observed with CyA/MP prophylaxis for patients with CML. After November 22, 1989, the next 16 sequential patients transplanted were administered CyA/ MTX in an attempt to reduce the incidence of systemic fungal infections, thought to be related in part to the prolonged use of systemic corticosteroids for GVHD prophylaxis. The first 10 patients received MTX 15 mg/m2 IV on day 1, and 10 mg/m2 IV on days 3,6, and 11," with MTX doses held if the serum bilirubin was greater than 2.0 mg/dL, or if the serum aspL tate aminotransferase (AST) was greater than two times normLC The next 10 patients received MTX 10 mg/m2 on days 1, 3, and 6.12 Doses of MTX in this group were also held if the bilirubin exceeded two times the bilirubin level obtained on day 0. No MTX was administered if the serum creatinine was greater than 2.0 mg/dL.
The syndrome of VOD was diagnosed when at least two of the following parameters were present within 30 days after transplant: jaundice (bilirubin > 3.0 mg/dL), hepatomegaly, right upper quadrant pain, and fluid accumulation evidenced by ascites or unexplained weight gain. These parameters were collected prospectively using a computerized database. Clinical computer database entries were merged with the laboratory database to help determine the incidence of VOD.
Estimates of survival probabilities were computed by using the methods of Kaplan and Meier. 13 Other comparisons used Pearson chi square with Yate's correction for continuity and Student's t-tests.'4 100,000/~m3.
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RESULTS
Eighty-seven patients underwent transplant preparation with Bu&y2 and received bone marrow from a human lymphocyte antigen (HLA) identical, or single antigen mismatched, related donor with supportive care as described in Materials and Methods. Sixty-seven patients received CyA/MP, and 20 patients were administered CyAIMTX for prevention of acute GVHD. Patient characteristics are shown in Table 1 . While age and sex distribution were similar for the two groups, pretransplant AST levels were elevated in 12 of 67 patients (17.9%) receiving CyAIMP versus no elevation in any patient receiving CyAlMTX. No patient had an elevated bilirubin at the time of initiation of transplant preparation. In general, patients administered CyA/MP had more advanced hematologic disease and were more heavily pretreated than patients in the CyAlMTX group (Table 1) . No patient received busulfan as treatment for their disease at any time before transplantation. Ten of 20 patients (50%) required MTX dosage reductions according to parameters listed in Materials and Methods. Overall MTX dose intensity was 56 of 80 possible doses, or 70% of calculated dose. Of particular note, 4 of 20 patients (20%) developed early hyperbilirubinemia (before day +3) and later met criteria for VOD. Three quarters of these patients were in the cohort who received the 10 mg/m2 dose on day 1, and one quarter went on to die of VOD.
Other clinical parameters are summarized in Table 2 . The mean daily bilirubin was computed for patients admin- *Differences between patients with prior chemotherapy, compared with those without prior chemotherapy, using the same GVHD prophylaxis regimen, were not significant. tPatients were eligible for evaluation if their donor was less than a two antigen mismatch, if they survived more than 30 days posttransplant and had evidence of engraftment, or if they had acute GVHD.
istered CyA/MP or CyA/MTX (Fig 1) . The mean maximal bilirubin during the first 30 days post-BMT for patients treated with CyA/MP was 4.67 2 7.27 mg/dLversus 8.72 f 8.73 mgidL for those receiving CyA/MTX (P = .04). Whereas bilirubin is plotted to day +30 for both groups, raising the possibility for hyperbilirubinemia resulting from causes other than VOD such as sepsis, GVHD, or cyclosporine toxicity; patients who met criteria for VOD all had a bilirubin greater than 3.0 mg/dL by day +14 after transplant. Conversely, no patient who developed hepatic toxicity due to other causes had an elevated bilirubin on day + 14, and the mean day of maximum bilirubin elevation was day +16. The incidence of fever and sepsis posttransplant, and the duration of antibiotic and antifungal therapy, was similar for both groups.
Forty-eight percent of patients administered CyA/MP developed hyperbilirubinemia (bilirubin > 2.0 mg/dL) compared with 80% in the CyA/MTX group (P = .02). In addition to an increase in the incidence of hyperbilirubinemia, there was also an increase in the maximal bilirubin elevation seen posttransplantation, and in the number of patients meeting clinical criteria for the diagnosis of VOD. The incidence of VOD increased from 12 of 67 (18%) to 14 of 20 (70%) with the substitution of methotrexate for MP in the GVHD prophylactic regimen (P < .01). Three of 67 patients (4.5%) receiving CyA/MP versus five of 20 patients (20%) receiving CyA/MTX died secondary to VOD (P = .02). Among patients who developed VOD, the incidence of VOD death increased from 3 of 12 (25%) using CyA/MP to 5 of 14 (35%) with CyAiMTX, but was not statistically significant (P = .68).
Overall survival for the two groups is shown in Fig 2. The CyA/MTX curve is remarkable for earlier deaths caused by VOD, but there was no statistically significant difference in survival beyond 100 days between the two groups (P = .77).
DISCUSSION
VOD of the liver complicating BMT was first described in 1979. 15 The clinical diagnosis of VOD has been shown to be predictive of histologic evidence of VOD in approximately 90% of VOD occurs after transplant preparation with many different cytotoxic drug and/or TBI containing regimens.'' The incidence of VOD was 21% in 255 patients transplanted for hematologic malignancies using a variety of preparative regimen^.^,^ In a series of 235 patients treated with CTX and TBI (Cy/TBI), or Bu4Cy4, VOD was the third leading cause of death, after GVHD and infection.16 Indeed, hepatic dysfunction was the most common regimen-related toxicity reported in a review of patients treated with CyITBI, with the observation that all patients who developed grade 111-IV liver toxicity died before day 100.ls For
INCREASED VOD WITH MTX GVHD PROPHYLAXIS
Drugs other than those used in the preparative regimen can also contribute to hepatic toxicity in patients undergoing allogeneic BMT. MTX hepatotoxicity was first described in 1955 manifesting as an increased prevalence of hepatic fibrosis at autopsy among children who had received MTX as part of their treatment for 1e~kemia.l~ Since that time, numerous descriptions of hepatic injury caused by MTX have been reported. The hepatic effects have included steatosis, nuclear pleomorphism, sinusoidal dilatation, as well as fibrosis and cirrh~sis.~O-~~ When MTX was added to CyA for acute GVHD prophylaxis in leukemic patients treated with CyITBI, a significant increase in bilirubin levels was observed during the first 14 days after marrow infusion in patients who received CyAI MTX compared with CyA alone. The mean peak bilirubin observed increased from 2.6 mg/dL, in patients receiving CyA alone, to 3.9 mg/dL in patients treated with CyA/ MTX ( P = .015).11924,25 Importantly, this elevation of bilirubin was not associated with an increased incidence of VOD, mortality, or length of hospital stay. When the CyAIMTX combination was used for GVHD prophylaxis for patients with severe aplastic anemia, a group of patients historically at low risk for hepatotoxicity caused by pretransplant conditioning with CTX alone, an increased incidence of hyperbilirubinemia has been observed p o s t t r a n~p l a n t .~~~~~ Of note, one patient who received CyAIMTX died of VOD.
The reported incidence of VOD after transplant preparation with Bu4Cyz to date is lower than that published for CyITBI. Tutschka et aI8 reported 50 patients with hematologic malignancies, administered CyAIMP for GVHD prophylaxis, with a VOD rate of only 2%. Using the same regimen, Brodsky et a19 reported a 10.8% incidence of VOD in 37 patients. MTX was not used to prevent GVHD in either series.
Our initial 67 patients, administered the identical Bu4Cy2 preparative regimen and CyA/MP GVHD prophylaxis, experienced a baseline incidence of VOD of 18%. Whereas this was comparable to CyITBI treated cohorts, systemic fungal infections occurred in 20% of our patients, of whom 93% subsequently died as a result. In an attempt to decrease fungal morbidity and mortality we decided to investigate the role of CyAIMTX for GVHD prophylaxis, reasoning that prolonged corticosteroid administration according to the CyA/MP GVHD prophylactic regimen was the most likely risk factor for the development of fungal infection.
The change to CyAIMTX for GVHD prophylaxis did result in a nonsignificant decrease in the incidence of systemic fungal infection and deaths caused by fungemia. However, a marked concomitant increase in the incidence of VOD was observed without any change in other supportive measures. The first 10 patients of the CyAiMTX cohort received the traditional IV MTX dosing." As seven of these patients developed VOD, we decreased the dose of MTX for the next 10 patients per Deeg et aL1* No significant decrease in VOD occurred, as seven of these next 10 patients receiving this MTX dose schedule also developed VOD. Although a statistically significant difference in the incidence of death from VOD was noted in patients receiving CyA/MTX (25%) versus those receiving CyA/MP (4.5%) (P = .02), overall survival was not significantly different between the two groups (Fig 2) . Although not statistically significant, this observation may in part be attributable to the lower incidence of acute GVHD (18.2% v 32.8%) (P = .54), and systemic fungal infection (10% v 20%) (P = .43) for those receiving CyA/MTX versus CyA/ MP, respectively.
Several factors should be explored in an attempt to explain the marked increase in the incidence of VOD for our patients who received CyAIMTX for GVHD prophylaxis. First, there is the possible VOD 'preventative' role that steroids may have when begun on day 7 posttransplant that, when omitted, increase the risk for VOD. We have treated 11 patients with the identical Bu4Cy2 regimen in preparation for autologous BMT for acute myelogenous leukemia. A bilirubin greater than 2.0 mg/dLwas noted in 3 of 11 (27.3%); 2 of 11 (18.2%) developed clinical VOD, and the mean maximum bilirubin for the group was 3.56 ? 4.69 mg/dL. These results are very similar to our allogeneic experience using Bu4Cy2 with CyAIMP GVHD prophylaxis, suggesting that the omission of corticosteroids had no effect on the incidence of hyperbilirubinemia or VOD.
A second possibility is that the combination of CyA/ MTX is more hepatotoxic when the CyA is dosed according to the CyA/MP schedule, ie, 5 mglkg for the first 96 hours posttransplant, which amounts to a 40% increase in dose intensity. CyA is known to be hepatotoxic.28 Although we realize the potential problems of comparing cohorts from other series, the Vancouver group has treated 57 patients with the identical Bu4Cy2 regimen using 'standard' doses of CyAIMTX noting a 51% incidence of grade 11-IV hepatotoxicity. 18929 The last factor that must be considered is the potential for differential oral absorption of busulfan, which can produce a marked variation in pharmacokinetics between patients as reported by Grochow et al.30 This study showed that the risk for VOD may be related to total drug exposure assessed by 'area under the curve' calculation. Future studies will have to properly address this when evaluating causal factors for VOD in patients receiving busulfan as a part of the preparative regimen.
CyAIMTX is an effective regimen for acute GVHD prophylaxis and has been shown to have acceptable toxicity when used following the Cy/TBI preparative regimen. While patients receiving CyAIMP and CyAIMTX for GVHD prophylaxis with the BuqCy2 preparative regimen had similar overall survival in our experience, hepatotoxicity was potentially severe with the use of CyA/MTX, and resulted in a significant increase in death resulting from VOD. Physicians using B u~Q~, or other busulfan containing preparative regimens must be aware of the potential for serious liver toxicity if CyA/MTX is used for GVHD prophylaxis. Additionally, investigators designing dose escalation protocols containing busulfan may wish to consider using GVHD prophylactic regimens that do not contain MTX. Future properly designed prospective randomized trials are warranted to study these issues.
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